Rhumbline Advisers Sells 57,100 Shares of Abbott Laboratories $ABT

Rhumbline Advisers lowered its stake in Abbott Laboratories (NYSE:ABT) by 1.8% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 3,036,362 shares of the healthcare product maker’s stock after selling 57,100 shares during the quarter. Rhumbline Advisers’ holdings in Abbott Laboratories were worth $406,692,000 at the end of the most recent reporting period.

Several other large investors also recently made changes to their positions in the stock. IMG Wealth Management Inc. boosted its stake in Abbott Laboratories by 759.1% in the 2nd quarter. IMG Wealth Management Inc. now owns 189 shares of the healthcare product maker’s stock worth $26,000 after purchasing an additional 167 shares during the period. Cloud Capital Management LLC bought a new stake in shares of Abbott Laboratories in the third quarter valued at about $29,000. Guerra Advisors Inc bought a new position in shares of Abbott Laboratories during the third quarter worth about $31,000. Anfield Capital Management LLC raised its position in Abbott Laboratories by 81.3% in the 2nd quarter. Anfield Capital Management LLC now owns 232 shares of the healthcare product maker’s stock valued at $32,000 after buying an additional 104 shares during the last quarter. Finally, Delos Wealth Advisors LLC bought a new stake in Abbott Laboratories in the 2nd quarter valued at approximately $32,000. Institutional investors own 75.18% of the company’s stock.

Abbott Laboratories Trading Up 1.0%

Shares of NYSE:ABT opened at $112.23 on Wednesday. Abbott Laboratories has a 52-week low of $105.27 and a 52-week high of $141.23. The company has a debt-to-equity ratio of 0.23, a quick ratio of 1.24 and a current ratio of 1.70. The company has a market capitalization of $195.15 billion, a P/E ratio of 30.17, a price-to-earnings-growth ratio of 1.77 and a beta of 0.75. The company has a 50-day simple moving average of $120.24 and a 200 day simple moving average of $126.70.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 earnings per share for the quarter, hitting analysts’ consensus estimates of $1.50. Abbott Laboratories had a return on equity of 17.94% and a net margin of 14.72%.The firm had revenue of $11.46 billion for the quarter, compared to the consensus estimate of $11.80 billion. During the same quarter in the previous year, the business earned $1.34 earnings per share. The business’s revenue was up 4.4% compared to the same quarter last year. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. Sell-side analysts forecast that Abbott Laboratories will post 5.14 earnings per share for the current year.

Abbott Laboratories Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, February 13th. Shareholders of record on Thursday, January 15th will be issued a $0.63 dividend. The ex-dividend date of this dividend is Thursday, January 15th. This represents a $2.52 annualized dividend and a yield of 2.2%. This is an increase from Abbott Laboratories’s previous quarterly dividend of $0.59. Abbott Laboratories’s payout ratio is currently 67.74%.

Wall Street Analysts Forecast Growth

ABT has been the topic of a number of recent research reports. Daiwa Securities Group lowered their price objective on shares of Abbott Laboratories from $136.00 to $113.00 and set an “outperform” rating on the stock in a report on Friday, January 30th. Mizuho lifted their price target on shares of Abbott Laboratories from $135.00 to $140.00 and gave the company a “neutral” rating in a research note on Tuesday, October 14th. Freedom Capital upgraded shares of Abbott Laboratories from a “hold” rating to a “strong-buy” rating in a research note on Thursday, January 29th. Royal Bank Of Canada decreased their price objective on Abbott Laboratories from $147.00 to $135.00 and set an “outperform” rating for the company in a report on Friday, January 23rd. Finally, The Goldman Sachs Group dropped their target price on Abbott Laboratories from $152.00 to $140.00 and set a “buy” rating on the stock in a report on Friday, January 23rd. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $137.05.

Insider Activity

In other news, Director Daniel J. Starks bought 10,000 shares of the firm’s stock in a transaction dated Wednesday, February 4th. The shares were bought at an average price of $108.73 per share, with a total value of $1,087,300.00. Following the completion of the transaction, the director owned 6,738,817 shares of the company’s stock, valued at $732,711,572.41. This trade represents a 0.15% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website. 0.46% of the stock is currently owned by corporate insiders.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.